Case Report
Copyright ©2013 Baishideng. All rights reserved.
World J Hematol. May 6, 2013; 2(2): 59-61
Published online May 6, 2013. doi: 10.5315/wjh.v2.i2.59
Autologous lymphocytes infusion
Luis F Porrata, Svetomir N Markovic
Luis F Porrata, Svetomir N Markovic, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: Porrata LF and Markovic SN were attending doctors for the patients, organized the report and wrote the paper.
Correspondence to: Luis F Porrata, MD, Assistance Professor, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States.
Telephone: +1-507-2843158 Fax: +1-507-2843158
Received: February 8, 2013
Revised: March 21, 2013
Accepted: April 10, 2013
Published online: May 6, 2013

The graft vs tumor effect produced by the infusion of allo-reactive lymphocytes is considered to be the main mechanism of action in the eradication of tumor cells only reported in allogeneic stem cell transplantation. We present a case of a lymphoma patient infused with his collected bystander lymphocytes from is stem cell autograft after failing to collect enough stem cells to proceed with autologous stem cells transplantation, resulting in tumor response with no treatment related toxicity. This case illustrates the concept of autologous lymphocyte infusion, suggesting the possibility of an autograft vs tumor effect, as an effort to parallel donor lymphocyte infusion in allogeneic stem cell transplantation to create a graft vs tumor effect by increasing donor lymphocytes in the patient.

Keywords: Autologous lymphocytes infusion, Autograft vs tumor effect, Natural killer cells, Tumor regression, Survival

Core tip: This case report illustrated the possibility of an autograft vs tumor effect by infusion autologous lymphocytes collected during stem cell collection without the side effect graft vs host disease. The infusion of autologous lymphocytes produced tumor regression in our case, suggesting that this treatment modality might benefit lymphoma patients.